(Q43195216)

15 November 2017

96-week efficacy and safety of atazanavir, with and without ritonavir, in a HAART regimen in treatment-naive patients (English)

1 reference

15 November 2017

1 reference

1 reference

6

Uchenna H Iloeje

1 reference

15 November 2017

D R Niel Malan

1

1 reference

15 November 2017

Edrich Krantz

2

1 reference

15 November 2017

Neal David

3

1 reference

15 November 2017

Rong Yang

4

1 reference

15 November 2017

Marina Mathew

5

1 reference

15 November 2017

Jun Su

7

1 reference

15 November 2017

Donnie McGrath

8

1 reference

15 November 2017

089 Stuy Group

9

1 reference

15 November 2017

1 January 2010

1 reference

Journal of the International Association of Providers of AIDS Care

15 November 2017

1 reference

15 November 2017

9

1 reference

15 November 2017

1

1 reference

15 November 2017

34-42

1 reference

Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel

15 November 2017

1 reference

https://api.crossref.org/works/10.1177%2F1545109709355828

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109709355828

96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109709355828

Dual protease inhibitor therapy in HIV-infected patients: pharmacologic rationale and clinical benefits

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109709355828

The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109709355828

Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109709355828

Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109709355828

Highly active antiretroviral treatment (HAART) and health-related quality of life in naive and pretreated HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109709355828

Long-term quality of life outcomes in three antiretroviral treatment strategies for HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109709355828

Evidence for reliability, validity and usefulness of the Medical Outcomes Study HIV Health Survey (MOS-HIV).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109709355828

Failure of lopinavir-ritonavir (Kaletra)-containing regimen in an antiretroviral-naive patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109709355828

Isolated lopinavir resistance after virological rebound of a ritonavir/lopinavir-based regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109709355828

Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109709355828

Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109709355828

Combination antiretroviral therapy and the risk of myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109709355828

Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109709355828

Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109709355828

Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109709355828

Assessing the effect of HAART on change in quality of life among HIV-infected women

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109709355828

The role of adherence to antiretroviral therapy in the management of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109709355828

Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109709355828

Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109709355828

The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1545109709355828

21 January 2018

Identifiers

DOI

10.1177/1545109709355828

1 reference

15 November 2017

1 reference